UNSPSC 51314307: Chlorpheniramine/citric acid/guaifenesin/phenylpropanolamine/sodium citrate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE503. This VA Drug Class (RE503) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/EXPECTORANT.

UNSPSC 51314307 Chlorpheniramine/citric acid/guaifenesin/phenylpropanolamine/sodium citrate is a Commodity code that maps poorly to actual state and local procurement activity; recent opportunities tagged under this code reflect a substantial mismatch with its nominal pharmaceutical formulation scope. The single recent solicitation in the record—Seminole County, Florida's IFB for naloxone and drug deactivation systems—involves procurement of naloxone (an opioid antagonist used in overdose response) and safe drug deactivation equipment for community health support, neither of which aligns with the code's named active ingredients. State and local purchasing offices appear to have applied this code inconsistently or as a placeholder, suggesting either a data-classification error or a relabeling of the procurement post-award.

Seminole County's IFB 60459723LAS, posted June 30, 2026, with a due date of July 26, 2023, solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually on a competitive bid basis, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Bidders were required to submit bids electronically, include all shipping and delivery costs, and comply with drug-free workplace certification and E-Verify requirements. The contract carried a two-year initial term with an optional one-year renewal, and vendors were subject to standard insurance and compliance obligations; FEMA funding potentially applied, introducing federal clean air and water pollution control requirements. The code shows minimal recent activity and little evidence of sustained or broad state and local demand under its stated pharmaceutical scope; interested vendors should verify the accuracy of code assignment before pursuing similar opportunities.